Send to

Choose Destination
Hepatol Res. 2018 Nov 28. doi: 10.1111/hepr.13292. [Epub ahead of print]

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.

Author information

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Core Research Facilities for Basic Science, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Department of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Japan.
Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Department of Internal Medicine, Division of Gastroenterology Hepatology, Tokyo Medical University, Ibaraki Medical Center, Ibaraki, Japan.
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.



The aim of this study was to evaluate the efficacy and safety of community-based ombitasvir/paritaprevir/ritonavir plus ribavirin therapy for non-cirrhotic patients with hepatitis C virus (HCV) genotype 2a infection in a real-world setting.


Patients with HCV genotype 2a infection were enrolled in this study and received the therapy for 16 weeks at 11 specialized centers between October 2016 and July 2017. Among the 98 patients participating in the study, 4 patients were excluded because of the presence of cirrhosis and/or genotype 2b infection. The remaining 94 patients were subjected to the analysis.


The patients consisted of 38 females and 56 males, with a median age of 63 years. The rate of sustained virologic response (SVR) was 97.9%. The SVR rates were similar between patients with and without ribavirin dose reduction (96.0% versus 98.6%, respectively). Of the 2 patients in whom treatment failed, 1 patient completed the treatment but relapse at 4 weeks post-treatment, whereas the other did not show virologic response and therefore discontinued treatment at week 9. At baseline, both patients had NS5A resistance-associated substitution (RAS) L31M but did not have any NS3 RASs. At the time of relapse, the patient had NS5A RAS F28S. At the premature treatment discontinuation, the non-responder had NS3 RAS D168V and NS5A RAS T24S. Ribavirin-induced anemia was the most frequent adverse event.


Community-based, 16-week, ombitasvir/paritaprevir/ritonavir plus ribavirin therapy was highly efficacious and safe in non-cirrhotic patients with HCV genotype 2a infection in a real-world setting.


chronic hepatitis; genotype 2a; ombitasvir/paritaprevir/ritonavir; ribavirin


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center